Navigation Links
Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
Date:2/10/2011

clinical candidates will not proceed to later stage clinical trials; and risk that the Company's research programs will not identify pre-clinical candidates for further development. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2009 and Form 10-Q for the quarter ended September 30, 2010. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.NEUROCRINE BIOSCIENCES, INC.Condensed Consolidated Statements of Operations(in thousands, except for per share data)Three Months Ended
December 31,Year Ended
December 31,2010200920102009(unaudited)(unaudited)Revenues:Sponsored research and development

$ 4,419$   11$10,938$
34License fees and milestones

9,23872922,5632,919Total revenues

13,65774033,5012,953Operating expenses:Research and development

8,0656,75331,15133,722General and administrative

3,3232,84113,27314,360Cease-use expense

2,3981262,7995,984Restructuring expense

———2,557Total operating expenses

13,7869,72047,22356,623Loss from operations

(129)(8,980)(13,722)(53,670)Other income:Gain on sale of fixed assets

92108294841Other income, net

2,5249565,4601,791Total other income

2,6161,0645,7542,632Net income (los
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
2. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
3. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
4. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
6. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
7. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
8. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
9. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
10. Neurocrine Biosciences Amends Corporate Headquarters Lease
11. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... life-threatening diseases, today announced that it will host its ... on Thursday, August 13, 2015 at 4:30 p.m. Eastern ... the release of fiscal 2016 first quarter results.  A ... two hours after the call at the Investor Relations ...
(Date:8/3/2015)... , August 3, 2015 ... Study on 3D Cell Culture: Asia ... Persistence Market Research, the global 3D cell culture market was valued ... to expand at a CAGR of 29.1% to account ... Full Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp 3D ...
(Date:7/31/2015)... , July 31, 2015 In today,s ... that help them drive positive health outcomes, improve ... source of patient care in their communities. At ... tradeshow and conference, AmerisourceBergen announced a new set ... Services Administration Organization and help independent pharmacies endure ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... and quantification of partially hydrolyzed gluten in foods, has been accepted by AOAC ... method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based ...
Breaking Biology Technology:Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... alarming pace, a University of Central Florida research team is ... a miniature diagnostic toolkit in the hopes of stimulating earlier ... the National Science Foundation for up to $600,000 over three ... of a credit card to detect damaging levels of oxygen ...
... Protection Agency today outlined a new research strategy ... human health and the environment. Nanomaterials are materials ... A nanometer is approximately 1/100,000 the width of ... in hundreds of consumer products, including sunscreen, cosmetics ...
... ... new ClearTrial TRACK provides integrated planning, outsourcing, project tracking, reforecasting, accrual management, and ... ... www.cleartrial.com ), the leading provider of Clinical Trial Operations (CTO) software, announced today ...
Cached Biology Technology:UCF team developing tool kit to help diagnose dementia 2EPA announces research strategy to study nanomaterials 2ClearTrial Launches Industry-first Software Platform for Integrating Clinical Trial Operations from Plan to Cash™, Driving Operational Efficiencies and Accelerating Clinical Development 2ClearTrial Launches Industry-first Software Platform for Integrating Clinical Trial Operations from Plan to Cash™, Driving Operational Efficiencies and Accelerating Clinical Development 3ClearTrial Launches Industry-first Software Platform for Integrating Clinical Trial Operations from Plan to Cash™, Driving Operational Efficiencies and Accelerating Clinical Development 4
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... -- Die 10. internationale Konferenz zu Genomik (ICG-10, ... findet vom 22. bis 25. Oktober 2015 in ... Die Konferenz feiert in diesem Jahr ... die ICG weltweit zu einem der einflussreichsten jährlichen ... der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
(Date:7/27/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Huawei has selected the Synaptics ® ... stylish smartwatch. Huawei chose the state-of-the-art ClearPad capacitive ... and highly responsive human interface qualities such as ... required a classic round watch face and Synaptics ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... the human mind in the hope of answering some ... to the nature of knowledge. Today cognitive scientists link ... research in various areas, an approach epitomized by WIREs ... The content of this journal will be free for ...
... Iowa - Research at Iowa State University has led scientists ... and eventually kills them. A research team led by Gaya ... had previously solved the structure of a critical part of ... host immune suppression. Amarasinghe and his research team now know ...
... GAINESVILLE, Fla. The University of Florida,s Institute on ... National Institutes of Health to construct an almost 40,000-square-foot ... building will bring together scientists from a range of ... out on the campus. "This is a unique ...
Cached Biology News:Iowa State University researcher discovers Ebola's deadly secret 2UF gets almost $15 million in federal funds to build research complex to help older adults 2UF gets almost $15 million in federal funds to build research complex to help older adults 3
...
Mouse monoclonal [2Q2147] to Aequorin ( Abpromise for all tested applications)....
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
... mixed TAMRA isomers are predominantly used for ... preferred for labeling peptides and nucleotides because ... that is often required in the conjugation ... 6-TAMRA for labeling peptides and proteins. 6-TAMRA ...
Biology Products: